CURRENT
ISSUE
1722

Nemolizumab (Nemluvio – Galderma), a subcutaneously injected interleukin-31 (IL-31) receptor antagonist, has been approved by the FDA for use in combination with topical corticosteroids and/or calcineurin inhibitors for treatment of moderate to severe atopic dermatitis in patients ≥12 years old whose disease is not adequately controlled with topical prescription drugs. It is the first IL-31 receptor antagonist to be approved in the US for this indication. Nemolizumab was approved earlier for treatment of prurigo nodularis in adults.

THE DISORDER — Atopic dermatitis (also known as...  Continue reading

Coming Soon
Drugs for Dry Eye Disease
Tapinarof (Vtama) Cream for Atopic Dermatitis
A Renal Indication for Semaglutide (Ozempic)